| United States valuation of EQ-5D-5L health states using an international protocol AS Pickard, EH Law, R Jiang, E Pullenayegum, JW Shaw, F Xie, M Oppe, ... Value in health 22 (8), 931-941, 2019 | 238 | 2019 |
| US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples R Jiang, MFB Janssen, AS Pickard Quality of Life Research 30, 803-816, 2021 | 111 | 2021 |
| The societal cost of heroin use disorder in the United States R Jiang, I Lee, TA Lee, AS Pickard PloS one 12 (5), e0177323, 2017 | 82 | 2017 |
| Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer AS Pickard, R Jiang, HW Lin, S Rosenbloom, D Cella Clinical therapeutics 38 (4), 769-777, 2016 | 59 | 2016 |
| E-prescribing: history, issues, and potentials JW Salmon, R Jiang Online journal of public health informatics 4 (3), 2012 | 54 | 2012 |
| Healthcare resource use, costs, and disease progression associated with diabetic nephropathy in adults with type 2 diabetes: a retrospective observational study Z Zhou, P Chaudhari, H Yang, AP Fang, J Zhao, EH Law, EQ Wu, R Jiang, ... Diabetes Therapy 8, 555-571, 2017 | 42 | 2017 |
| Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors ID Ursan, R Jiang, EM Pickard, TA Lee, D Ng, AS Pickard Journal of Managed Care & Specialty Pharmacy 21 (2), 114-122, 2015 | 32 | 2015 |
| Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off R Jiang, J Shaw, A Mühlbacher, TA Lee, S Walton, T Kohlmann, ... Quality of Life Research 30, 1433-1444, 2021 | 24 | 2021 |
| A pharmacogenetics service experience for pharmacy students, residents, and fellows K Drozda, Y Labinov, R Jiang, MR Thomas, SS Wong, S Patel, ... American journal of pharmaceutical education 77 (8), 175, 2013 | 22 | 2013 |
| Exploring the internal structure of the EQ-5D using non–preference-based methods YS Feng, R Jiang, T Kohlmann, AS Pickard Value in Health 22 (5), 527-536, 2019 | 14 | 2019 |
| Combining EQ-5D-5L items into a level summary score: demonstrating feasibility using non-parametric item response theory using an international dataset YS Feng, R Jiang, AS Pickard, T Kohlmann Quality of Life Research, 1-13, 2021 | 13 | 2021 |
| Current treatment approaches and global consensus guidelines for brain metastases in melanoma XL Tan, A Le, FC Lam, E Scherrer, RG Kerr, AC Lau, J Han, R Jiang, ... Frontiers in Oncology 12, 885472, 2022 | 12 | 2022 |
| Clinical trajectories, healthcare resource use, and costs of diabetic nephropathy among patients with type 2 diabetes: a latent class analysis R Jiang, E Law, Z Zhou, H Yang, EQ Wu, R Seifeldin Diabetes therapy 9, 1021-1036, 2018 | 11 | 2018 |
| Real-world therapy with Pembrolizumab: outcomes and Surrogate endpoints for predicting survival in advanced Melanoma patients in Germany P Mohr, E Scherrer, C Assaf, M Bender, C Berking, S Chandwani, ... Cancers 14 (7), 1804, 2022 | 8 | 2022 |
| Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study MA Khattak, JJ Luke, GV Long, PA Ascierto, P Rutkowski, D Schadendorf, ... European Journal of Cancer 176, 207-217, 2022 | 7 | 2022 |
| The role of personality in treatment-related outcome preferences among pharmacy students EH Law, R Jiang, A Kaczynski, A Mühlbacher, AS Pickard American Journal of Pharmaceutical Education 83 (7), 6891, 2019 | 6 | 2019 |
| United States valuation of EQ-5D-5L health States: An initial model using a standardized protocol AS Pickard, EH Law, R Jiang, M Oppe, JW Shaw, F Xie, KS Boye, ... Value in Health 21, S4-S5, 2018 | 6 | 2018 |
| Comparison of preferences and data quality between discrete choice experiments conducted in online and face-to-face respondents R Jiang, E Pullenayegum, JW Shaw, A Mühlbacher, TA Lee, S Walton, ... Medical Decision Making 43 (6), 667-679, 2023 | 4 | 2023 |
| Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. MA Khattak, JJ Luke, GV Long, PA Ascierto, P Rutkowski, D Schadendorf, ... Journal of Clinical Oncology 40 (16_suppl), 9581-9581, 2022 | 4 | 2022 |
| Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review XL Tan, A Le, H Tang, M Brown, E Scherrer, J Han, R Jiang, SJ Diede, ... Cancers 14 (24), 6108, 2022 | 3 | 2022 |
